Loading
Led PALOMA-2, which made palbociclib a first-line breast cancer drug, and IMbrave150, which made immunotherapy the standard for liver cancer.
Richard Finn was principal investigator of PALOMA-2, the trial that established palbociclib plus letrozole as first-line therapy for HR-positive advanced breast cancer and launched the CDK4/6 inhibitor class. He then led IMbrave150, which showed atezolizumab plus bevacizumab beat sorafenib in unresectable hepatocellular carcinoma, ending a decade of sorafenib as the only option. His current work covers next-generation CDK inhibitors and immunotherapy sequencing in liver cancer.
Shares CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares IMbrave150, IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer, Atezolizumab, PD-L1 and the tag hcc.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares CDK4/6, Palbociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag breast.
Shares the tags breast, trialist.
Shares IMbrave150, IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer, Atezolizumab, Hepatocellular carcinoma.
Shares PD-L1, Hepatocellular carcinoma, Immune checkpoint inhibitors and the tags hcc, trialist.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/